+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gouty Arthritis (Gout) - Pipeline Review, H2 2020

  • PDF Icon

    Drug Pipelines

  • 139 Pages
  • November 2020
  • Region: Global
  • Global Markets Direct
  • ID: 5229482
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gouty Arthritis - Pipeline Review, H2 2020, provides an overview of the Gouty Arthritis (Musculoskeletal Disorders) pipeline landscape.

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease and high intake of foods rich in purines.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Gouty Arthritis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gouty Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Unknown stages are 3, 14, 10, 1, 17 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Gouty Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gouty Arthritis (Musculoskeletal Disorders)

Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

Gouty Arthritis - Overview

Gouty Arthritis - Therapeutics Development

Gouty Arthritis - Therapeutics Assessment

Gouty Arthritis - Companies Involved in Therapeutics Development

Gouty Arthritis - Drug Profiles

Gouty Arthritis - Dormant Projects

Gouty Arthritis - Discontinued Products

Gouty Arthritis - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development for Gouty Arthritis (Gout), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Acquist Therapeutics, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Aequus BioPharma Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Allena Pharmaceuticals Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Arthrosi Therapeutics Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by C&C Research Laboratories, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by DevaCell Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Dianomi Therapeutics Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Dyve Biosciences Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Enzychem Lifesciences Corp, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Fochon Pharmaceutical Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by FortuneRock (China) Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Fuji Yakuhin Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by General Genomics Llc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by General Regeneratives Shanghai Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Hinova Pharmaceuticals Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Horizon Therapeutics Plc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by InflammatoRx inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by InventisBio Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by LG Chem Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Nippon Chemiphar Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Novartis AG, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Olatec Therapeutics LLC, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Opsona Therapeutics Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by PegBio Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Polaris Pharmaceuticals Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Protalix BioTherapeutics Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by R Pharm, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Rigel Pharmaceuticals Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Shanton Pharma Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Swedish Orphan Biovitrum AB, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Teijin Pharma Ltd, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by TWi Biotechnology Inc, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by Wellstat Therapeutics Corp, H2 2020
  • Gouty Arthritis (Gout) - Pipeline by XL-protein GmbH, H2 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H2 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H2 2020 (Contd..1), H2 2020
  • Gouty Arthritis (Gout) - Dormant Projects, H2 2020 (Contd..2), H2 2020
  • Gouty Arthritis (Gout) - Discontinued Products, H2 2020

List of Figures
  • Number of Products under Development for Gouty Arthritis (Gout), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Acquist Therapeutics
  • Aequus BioPharma Inc
  • Allena Pharmaceuticals Inc
  • Arthrosi Therapeutics Inc
  • C&C Research Laboratories
  • DevaCell Inc
  • Dianomi Therapeutics Inc
  • Dyve Biosciences Inc
  • Enzychem Lifesciences Corp
  • Fochon Pharmaceutical Ltd
  • FortuneRock (China) Ltd
  • Fuji Yakuhin Co Ltd
  • General Genomics Llc
  • General Regeneratives Shanghai Ltd
  • GeneScience Pharmaceuticals Co Ltd
  • Hinova Pharmaceuticals Inc
  • Horizon Therapeutics Plc
  • InflammatoRx inc
  • InventisBio Inc
  • Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • LG Chem Ltd
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Olatec Therapeutics LLC
  • Opsona Therapeutics Ltd
  • PegBio Co Ltd
  • Polaris Pharmaceuticals Inc
  • Protalix BioTherapeutics Inc
  • R Pharm
  • Rigel Pharmaceuticals Inc
  • Shanghai Yingli Pharmaceutical Co Ltd
  • Shanton Pharma Co Ltd
  • Swedish Orphan Biovitrum AB
  • TaiwanJ Pharmaceuticals Co Ltd
  • Teijin Pharma Ltd
  • TWi Biotechnology Inc
  • Wellstat Therapeutics Corp
  • XL-protein GmbH